{"id":3843,"date":"2019-01-02T07:53:17","date_gmt":"2019-01-02T07:53:17","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/"},"modified":"2019-01-02T07:53:17","modified_gmt":"2019-01-02T07:53:17","slug":"nanexas-pharmashell-patent-godkant-i-usa","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/","title":{"rendered":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA"},"content":{"rendered":"
\n

<\/strong><\/span><\/p>\n<\/div>\n

Amerikanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae.<\/span><\/p>\n

Nanexa har utvecklat ett drug delivery system – PharmaShell\u00ae\u00a0– f\u00f6r parenteral administrering av l\u00e4kemedel. PharmaShell\u00ae\u00a0m\u00f6jligg\u00f6r fris\u00e4ttning av l\u00e4kemedel under en l\u00e4ngre tid, fr\u00e5n ett par veckor till riktigt l\u00e5nga dep\u00e5tider p\u00e5 upp till ett \u00e5r. Dep\u00e5tiden kan, genom justeringar i tillverkningsprocessen av PharmaShell\u00ae, styras till \u00f6nskad l\u00e4ngd.<\/span><\/p>\n

PharmaShells\u00ae\u00a0egenskaper, med extremt h\u00f6g s\u00e5 kallad drug load och m\u00f6jlighet att styra den initiala fris\u00e4ttningen, g\u00f6r den unik p\u00e5 marknaden. De n\u00e4mnda egenskaperna \u00e4r ocks\u00e5 efterfr\u00e5gade av industrin f\u00f6r att skapa nya och mer effektiva l\u00e4kemedel med m\u00f6jlighet att begr\u00e4nsa l\u00e4kemedlets biverkningar.<\/span><\/p>\n

Det amerikanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan den 1 januari 2019. Det nu godk\u00e4nda patentet t\u00e4cker in sj\u00e4lva produkten PharmaShell\u00ae\u00a0samt metoden f\u00f6r dess tillverkning och formuleringar av PharmaShell\u00ae-belagda l\u00e4kemedel. Det godk\u00e4nda patentet har patentnummer US 10166198.<\/span><\/p>\n

F\u00f6retagets VD David Westberg kommenterar:<\/span><\/p>\n

Det \u00e4r med stor tillfredsst\u00e4llelse jag nu kan konstatera att PharmaShell\u00ae-patentet \u00e4r godk\u00e4nt i USA. Vi har hela tiden k\u00e4nt oss trygga i v\u00e5r patentsituation, men det betyder \u00e4nd\u00e5 mycket att f\u00e5 det bekr\u00e4ftat av det amerikanska patentverket. USA \u00e4r v\u00e5r st\u00f6rsta marknad och nu n\u00e4r vi har ett godk\u00e4nt patent hamnar vi i en mer intressant position i diskussioner med potentiella partners.<\/span><\/p>\n

V\u00e4gen fr\u00e5n inl\u00e4mnande av en patentans\u00f6kan till ett godk\u00e4nt patent \u00e4r l\u00e5ng och jag \u00e4r glad att vi i v\u00e5ras tog beslutet att skynda p\u00e5 processen genom att f\u00f6lja den s\u00e5 kallade\u201dTrack 1\u201d-rutinen hos amerikanska patentverket. Att vi tog initiativ till personlig intervju med granskaren i USA betydde troligtvis ocks\u00e5 mycket f\u00f6r att skynda p\u00e5 godk\u00e4nnandeprocessen.<\/span><\/p>\n

F\u00f6r mer information kontakta:
David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0<\/span><\/p>\n

Telefon: 0709 -42 83 03\u00a0<\/span><\/p>\n

E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n

Om Nanexa AB (publ)<\/span><\/p>\n

Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

L\u00e4s som pdf<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n

Amerikanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae.<\/p>\n

Nanexa har utvecklat ett drug delivery system – PharmaShell\u00ae\u00a0– f\u00f6r parenteral administrering av l\u00e4kemedel.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3843","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Amerikanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae. Nanexa har utvecklat ett drug delivery system – PharmaShell\u00ae\u00a0– f\u00f6r parenteral administrering av l\u00e4kemedel.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-usa\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-usa\\\/\",\"name\":\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-01-02T07:53:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-usa\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-usa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-pharmashell-patent-godkant-i-usa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB","og_description":"Amerikanska patentverket har godk\u00e4nt Nanexas patentans\u00f6kan avseende drug delivery-plattformen PharmaShell\u00ae. Nanexa har utvecklat ett drug delivery system – PharmaShell\u00ae\u00a0– f\u00f6r parenteral administrering av l\u00e4kemedel.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/","name":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-01-02T07:53:17+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-pharmashell-patent-godkant-i-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas PharmaShell\u00ae-patent godk\u00e4nt i USA"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}